SCHEMBL6229583

SCHEMBL6229583

Cc1ccc(Sc2ccccc2S(=O)(=O)/N=C/N(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
GAA P10253 1/20 0.54
HKDC1 Q2TB90 2/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
MAPT P10636 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
SLC6A9 P48067 1/20 0.36
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
HTR1A P08908 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 2/20 0.35
HTR3A P46098 2/20 0.35
DHFR P00374 1/20 0.34
POLB P06746 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6229585 1.00 LMNA (0.54) LMNAGAAHKDC1L3MBTL1TDP1
SCHEMBL489379 0.76 LMNA (0.58) LMNAGAAMAPTMEN1KMT2A
SCHEMBL7262048 0.76 GAA (0.67) LMNAGAANPSR1POLBSMN1; SMN2
SCHEMBL6232240 0.76 GAA (0.67) LMNAGAANPSR1POLBSMN1; SMN2
SCHEMBL6235192 0.73 LMNA (0.63) LMNAHKDC1L3MBTL1TDP1MAPT
SCHEMBL8096686 0.73 LMNA (0.49) LMNAGAAMAPTKMT2APOLB
SCHEMBL29751607 0.71 GAA (1.00) LMNAGAAMAPTMEN1KMT2A
SCHEMBL15761364 0.71 GAA (1.00) LMNAGAAMAPTMEN1KMT2A
SCHEMBL15436182 0.71 LMNA (0.46) LMNAGAAHKDC1L3MBTL1TDP1
SCHEMBL10530946 0.70 LMNA (0.49) LMNAGAAL3MBTL1TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1076651-B1 SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT AVENTIS PHARMA GMBH (DE) 2005-04-20 EP disclosed
US-6573288-B1 Compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-06-03 US disclosed
EP-1076651-A1 SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT Aventis Pharma Deutschland GmbH (DE) 2001-02-21 EP disclosed
WO-1999057102-A1 SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-11-11 WO disclosed